Narm.Bo
NARM.BO is a specialty chemicals company that produces and sells chemical products, primarily serving industrial and manufacturing sectors.
Business. NARM.BO is a specialty chemicals company that produces and sells chemical products, primarily serving industrial and manufacturing sectors.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NARM.BO is a specialty chemicals company that produces and sells chemical products, primarily serving industrial and manufacturing sectors.
NARM.BO has a relatively strong liquidity position, with a current ratio of 2.55, indicating that it holds more than twice as much in current assets as it does in current liabilities. However, the company's free cash flow is negative at -13.19 million INR, which suggests that capital expenditures are outpacing operating cash flow. The company's debt-to-equity ratio is 0.11, indicating a conservative capital structure with limited leverage.
In terms of profitability, NARM.BO's return on equity (ROE) is 14.41%, and its return on assets (ROA) is 10.8%, both of which are strong indicators of efficient use of equity and assets. The company's operating margin is 11.84% (calculated as operating income of 223.59 million INR divided by revenue of 1,889.21 million INR), which is a key metric for assessing operational efficiency in the specialty chemicals industry.
The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.
Looking ahead, NARM.BO is expected to maintain a stable growth trajectory, with no significant changes in revenue or operating income projected for the next fiscal year. The company's capital expenditures are expected to remain high, as evidenced by the -147.00 million INR in the most recent period, which may impact near-term profitability.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to avoid liquidity constraints. There is no indication of dilution pressure in the near term, as shares outstanding remain unchanged between basic and diluted counts.
Recent filings and transcripts do not indicate any material events or strategic shifts for NARM.BO. The company appears to be operating within its established business model without significant new initiatives or disruptions.
- NARM.BO has a strong ROE and ROA, indicating efficient use of equity and assets.
- The company's capital structure is conservative, with a low debt-to-equity ratio.
- Free cash flow is negative, suggesting that capital expenditures are outpacing operating cash flow.
- The company's revenue is concentrated in a single segment, which may increase business risk.
- There is no immediate dilution risk, and liquidity remains at a medium level.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- NARM.BO Market data — financials · 2026-05-28